Radioimmunotherapy for the treatment of infectious diseases : a comprehensive update
INTRODUCTION: Corona Virus Disease of 2019 (COVID-19) pandemic has renewed interest in monoclonal antibodies for treating infectious diseases. During last two decades experimental data has been accumulated showing the potential of radioimmunotherapy (RIT) of infectious diseases. In addition, COVID-19 pandemic has created a novel landscape for opportunistic fungal infections in post-COVID-19 patients resulting from severe immune suppression.
AREAS COVERED: We analyze recent results on targeting "pan-antigens" shared by fungal pathogens in mouse models and in healthy dogs; on developing RIT of prosthetic joint infections (PJI); examine RIT as potential human immunodeficiency virus (HIV) cure strategy and analyze its mechanisms and safety. Literature review was performed using PubMed and Google Scholar and includes relevant articles from 2000 to 2022.
EXPERT OPINION: Some of the RIT of infection applications can, hopefully, be moved into the clinic earlier than others after preclinical development: (1) RIT of opportunistic fungal infections might contribute to saving lives as current antifungal drugs do not work in severely immunocompromised patients; (2) RIT of patients with PJI. Success of RIT in these patients will allow to expand the application of RIT to other similarly vulnerable patients' populations such as cancer patients with weakened immune system and organ transplant recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Expert review of anti-infective therapy - 21(2023), 4 vom: 01. Apr., Seite 365-374 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carvalho, Jorge Luis Costa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacterial infection |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 27.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14787210.2023.2184345 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353216682 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353216682 | ||
| 003 | DE-627 | ||
| 005 | 20231226055509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14787210.2023.2184345 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353216682 | ||
| 035 | |a (NLM)36815406 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carvalho, Jorge Luis Costa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radioimmunotherapy for the treatment of infectious diseases |b a comprehensive update |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 27.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Corona Virus Disease of 2019 (COVID-19) pandemic has renewed interest in monoclonal antibodies for treating infectious diseases. During last two decades experimental data has been accumulated showing the potential of radioimmunotherapy (RIT) of infectious diseases. In addition, COVID-19 pandemic has created a novel landscape for opportunistic fungal infections in post-COVID-19 patients resulting from severe immune suppression | ||
| 520 | |a AREAS COVERED: We analyze recent results on targeting "pan-antigens" shared by fungal pathogens in mouse models and in healthy dogs; on developing RIT of prosthetic joint infections (PJI); examine RIT as potential human immunodeficiency virus (HIV) cure strategy and analyze its mechanisms and safety. Literature review was performed using PubMed and Google Scholar and includes relevant articles from 2000 to 2022 | ||
| 520 | |a EXPERT OPINION: Some of the RIT of infection applications can, hopefully, be moved into the clinic earlier than others after preclinical development: (1) RIT of opportunistic fungal infections might contribute to saving lives as current antifungal drugs do not work in severely immunocompromised patients; (2) RIT of patients with PJI. Success of RIT in these patients will allow to expand the application of RIT to other similarly vulnerable patients' populations such as cancer patients with weakened immune system and organ transplant recipients | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a bacterial infection | |
| 650 | 4 | |a fungal infections | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a prosthetic joint infections | |
| 650 | 4 | |a radioimmunotherapy | |
| 700 | 1 | |a Dadachova, Ekaterina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anti-infective therapy |d 2003 |g 21(2023), 4 vom: 01. Apr., Seite 365-374 |w (DE-627)NLM151540101 |x 1744-8336 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:4 |g day:01 |g month:04 |g pages:365-374 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14787210.2023.2184345 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 4 |b 01 |c 04 |h 365-374 | ||